SRR934864
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.387647831800263
- age_years
- 64
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.661
- INTERFERON_ALPHA_RESPONSE+0.649
- IL6_JAK_STAT3_SIGNALING+0.612
- ALLOGRAFT_REJECTION+0.592
- TNFA_SIGNALING_VIA_NFKB+0.562
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.556
- ANGIOGENESIS+0.533
- INFLAMMATORY_RESPONSE+0.517
- TGF_BETA_SIGNALING+0.448
- UNFOLDED_PROTEIN_RESPONSE+0.444
Top 10 suppressed
- KRAS_SIGNALING_DN-0.424
- SPERMATOGENESIS-0.330
- PANCREAS_BETA_CELLS-0.307
- OXIDATIVE_PHOSPHORYLATION-0.271
- BILE_ACID_METABOLISM-0.208
- FATTY_ACID_METABOLISM-0.125
- MYOGENESIS-0.123
- ESTROGEN_RESPONSE_LATE-0.076
- PEROXISOME-0.070
- HEME_METABOLISM-0.066
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934753 | — | — | 0.974 |
| 2 | SRR934747 | — | — | 0.971 |
| 3 | SRR934934 | — | — | 0.970 |
| 4 | SRR934845 | — | — | 0.970 |
| 5 | SRR934962 | — | — | 0.963 |
| 6 | SRR934932 | — | — | 0.963 |
| 7 | SRR934782 | — | — | 0.961 |
| 8 | SRR934881 | — | — | 0.957 |
| 9 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.957 |
| 10 | SRR934722 | — | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.661 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.649 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.612 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.592 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.562 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.556 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.533 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.517 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.448 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.444 | Idelalisib | — uncovered |
| APOPTOSIS | 0.431 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| COMPLEMENT | 0.425 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.411 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.385 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.368 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.367 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.365 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.358 | Remibrutinib | — uncovered |
| COAGULATION | 0.344 | Binimetinib | — uncovered |